VEGFA and neoplasm: Though several anti-angiogenic drugs, such as inhibitors of the vascular endothelial growth factor (VEGF) pathway, have been approved in clinical practice for the treatment of different tumor types, the results of clinical trials have not replicated the promising effects observed in preclinical models in terms of metastasis formation and progression2, 3.